Rosuvastatin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|aOrAn=a | |aOrAn=a | ||
|drugClass=[[HMG-CoA reductase inhibitor]] | |drugClass=[[HMG-CoA reductase inhibitor]] | ||
|indication=[[hyperlipidemia]] and mixed [[dyslipidemia]], [[hypertriglyceridemia]], [[primary dysbetalipoproteinemia]] ([[Type III hyperlipoproteinemia]]), [[homozygous familial hypercholesterolemia]], slowing of the progression of [[atherosclerosis]], primary prevention of [[cardiovascular disease]] | |indication=[[hyperlipidemia]] and mixed [[dyslipidemia]], [[hypertriglyceridemia]], [[primary dysbetalipoproteinemia]] ([[Type III hyperlipoproteinemia]]), [[homozygous familial hypercholesterolemia]], slowing of the progression of [[atherosclerosis]], primary prevention of [[cardiovascular disease]] | ||
|adverseReactions=[[headache]], [[myalgia]], [[abdominal pain]], [[asthenia]], and [[nausea]] | |adverseReactions=[[headache]], [[myalgia]], [[abdominal pain]], [[asthenia]], and [[nausea]] | ||
|blackBoxWarningTitle=Warning Title | |blackBoxWarningTitle=Warning Title | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
|fdaLIADAdult====== | |fdaLIADAdult======General Dosing Information===== | ||
* Dosing Information | * Dosing Information | ||
:* | :* 5 to 40 mg orally once daily. | ||
==== | ====Homozygous Familial Hypercholesterolemia==== | ||
* Dosing Information | * Dosing Information | ||
:* | :* 20 mg once daily | ||
|offLabelAdultGuideSupport======Condition 1===== | |offLabelAdultGuideSupport======Condition 1===== | ||
| Line 42: | Line 42: | ||
:* (Dosage) | :* (Dosage) | ||
|offLabelAdultNoGuideSupport====== | |offLabelAdultNoGuideSupport======Acute Coronary Syndrome===== | ||
==== | ====Prophylaxis for Age Related Macular Degeneration==== | ||
====Prophylaxis for Atrial Fibrillation==== | |||
====Prophylaxis for Cardiovascular Event in Percutaneous Coronary Intervention (PCI)==== | |||
====Prophylaxis for Venous Thromboembolism==== | |||
|fdaLIADPed======Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 to 17 years of age)===== | |||
===== | |||
* Dosing Information | * Dosing Information | ||
:* | :* 5‑20 mg/day; the maximum recommended dose is 20 mg/day | ||
|contraindications=* Condition 1 | |contraindications=* Condition 1 | ||
* Condition 2 | * Condition 2 | ||
Revision as of 14:41, 30 June 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Rosuvastatin is a HMG-CoA reductase inhibitor that is FDA approved for the {{{indicationType}}} of hyperlipidemia and mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia (Type III hyperlipoproteinemia), homozygous familial hypercholesterolemia, slowing of the progression of atherosclerosis, primary prevention of cardiovascular disease. Common adverse reactions include headache, myalgia, abdominal pain, asthenia, and nausea.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
General Dosing Information
- Dosing Information
- 5 to 40 mg orally once daily.
Homozygous Familial Hypercholesterolemia
- Dosing Information
- 20 mg once daily
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Acute Coronary Syndrome
Prophylaxis for Age Related Macular Degeneration
Prophylaxis for Atrial Fibrillation
Prophylaxis for Cardiovascular Event in Percutaneous Coronary Intervention (PCI)
Prophylaxis for Venous Thromboembolism
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 to 17 years of age)
- Dosing Information
- 5‑20 mg/day; the maximum recommended dose is 20 mg/day
Off-Label Use and Dosage (Pediatric)
Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5
Warnings
Conidition 1
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
| |
Rosuvastatin
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
Storage
There is limited information regarding Rosuvastatin Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Rosuvastatin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Rosuvastatin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
(Patient Counseling Information)
Precautions with Alcohol
Alcohol-Rosuvastatin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Rosuvastatin Brand Names in the drug label.
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.